+

PE20081441A1 - Subtipo de amidas selectivas de diazabicicloalcanos - Google Patents

Subtipo de amidas selectivas de diazabicicloalcanos

Info

Publication number
PE20081441A1
PE20081441A1 PE2007001487A PE2007001487A PE20081441A1 PE 20081441 A1 PE20081441 A1 PE 20081441A1 PE 2007001487 A PE2007001487 A PE 2007001487A PE 2007001487 A PE2007001487 A PE 2007001487A PE 20081441 A1 PE20081441 A1 PE 20081441A1
Authority
PE
Peru
Prior art keywords
subtype
ilcarbonyl
octane
diazabicicloalkanes
amidas
Prior art date
Application number
PE2007001487A
Other languages
English (en)
Inventor
Lan Miao
V Srinivasa Murthy
Regina Whitaker
Scott R Breining
Matt S Melvin
Anatoly A Mazurov
Yun-De Xiao
Philips S Hammond
Craig H Miller
Srinivisa Rao Akireddy
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PE20081441A1 publication Critical patent/PE20081441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 0-1; Cy ES 2-FURANILO, 3-FURANILO, 2-OXAZOLILO, 2-TIAZOLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(FURAN-2-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; N-(3-METILFURAN-2-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; N-(1,2,4-TIADIAZOL-5-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; ENTRE OTROS. DICHOS COMPUESTOS MODULAN LA ACTIVIDAD DE RECEPTORES NICOTINICOS NEURONALES DE ACETILCOLINA DEL SUBTIPO ALFA4BETA2 UTILES EN EL TRATAMIENTO DE DEMENCIA SENIL, DISLEXIA, ESQUIZOFRENIA, DEMENCIA VASCULAR, ENTRE OTROS
PE2007001487A 2006-11-02 2007-10-31 Subtipo de amidas selectivas de diazabicicloalcanos PE20081441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02

Publications (1)

Publication Number Publication Date
PE20081441A1 true PE20081441A1 (es) 2008-10-30

Family

ID=39233054

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011000136A PE20110671A1 (es) 2006-11-02 2007-10-31 Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
PE2007001487A PE20081441A1 (es) 2006-11-02 2007-10-31 Subtipo de amidas selectivas de diazabicicloalcanos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011000136A PE20110671A1 (es) 2006-11-02 2007-10-31 Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina

Country Status (33)

Country Link
US (6) US8114889B2 (es)
EP (2) EP2284171B1 (es)
JP (2) JP5539723B2 (es)
KR (2) KR20100124356A (es)
CN (4) CN102942569B (es)
AR (2) AR063451A1 (es)
AT (2) ATE545646T1 (es)
AU (2) AU2007317433B2 (es)
BR (2) BRPI0722387A2 (es)
CA (1) CA2663925C (es)
CL (1) CL2007003155A1 (es)
CO (1) CO6180435A2 (es)
CY (1) CY1112374T1 (es)
DK (1) DK2094703T3 (es)
ES (2) ES2395212T3 (es)
HK (2) HK1149751A1 (es)
HR (1) HRP20110570T1 (es)
IL (2) IL197618A (es)
MX (1) MX2009004801A (es)
MY (2) MY156730A (es)
NO (1) NO20091251L (es)
NZ (2) NZ587847A (es)
PE (2) PE20110671A1 (es)
PL (1) PL2094703T3 (es)
PT (1) PT2094703E (es)
RS (1) RS51834B (es)
RU (2) RU2517693C2 (es)
SA (1) SA07280584B1 (es)
SI (1) SI2094703T1 (es)
TW (3) TWI404532B (es)
UA (2) UA106718C2 (es)
UY (1) UY30686A1 (es)
WO (1) WO2008057938A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
KR20100122508A (ko) * 2008-03-05 2010-11-22 타가셉트 인코포레이티드 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
CN102143963A (zh) * 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010125082A1 (en) 2009-04-30 2010-11-04 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2011061751A1 (en) 2009-11-18 2011-05-26 Suven Life Sciences Limited BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
NZ601088A (en) 2009-12-29 2013-08-30 Suven Life Sciences Ltd Alpha 4 beta 2 neuronal nicotinic acetylcholine receptor ligands
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
EP3122750B1 (en) 2014-03-26 2019-09-04 F.Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
AU2015336216B2 (en) 2014-10-20 2020-05-21 Oyster Point Pharma, Inc. Methods of treating ocular conditions
AU2016316717B2 (en) 2015-09-04 2021-02-18 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
MX2017015034A (es) * 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
PE20180461A1 (es) 2015-09-24 2018-03-06 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de la atx
PE20180552A1 (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
EA201892265A1 (ru) 2016-04-07 2019-04-30 Ойстер Поинт Фарма, Инк. Способы лечения офтальмологических заболеваний
WO2018167001A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual atx/ca inhibitors
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
US10208052B1 (en) 2017-03-20 2019-02-19 Forma Therapeutics, Inc. Compositions for activating pyruvate kinase
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
WO2021055807A1 (en) 2019-09-19 2021-03-25 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
AU699465B2 (en) * 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
AU1996301A (en) * 1999-12-14 2001-06-25 Neurosearch A/S Novel heteroaryl-diazabicycloalkanes
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
MXPA04000012A (es) * 2001-07-06 2004-05-21 Neurosearch As Compuestos novedosos, su preparacion y uso.
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
NZ540998A (en) * 2003-02-27 2008-06-30 Neurosearch As Novel diazabicyclic aryl derivatives
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
DK1761542T3 (da) * 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
ATE427311T1 (de) * 2004-07-22 2009-04-15 Cumbre Pharmaceuticals Inc (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
JP2008540575A (ja) * 2005-05-13 2008-11-20 レキシコン・ファーマシューティカルズ・インコーポレーテッド 多環系化合物とその使用の方法
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
HK1149751A1 (en) 2011-10-14
US9580434B2 (en) 2017-02-28
MY145602A (en) 2012-03-15
KR20090074051A (ko) 2009-07-03
CN102942569A (zh) 2013-02-27
IL209026A0 (en) 2011-01-31
PL2094703T3 (pl) 2011-10-31
TW200826935A (en) 2008-07-01
JP5539723B2 (ja) 2014-07-02
TW201114424A (en) 2011-05-01
RU2009120674A (ru) 2010-12-10
NO20091251L (no) 2009-05-28
ES2395212T3 (es) 2013-02-11
US20100173932A1 (en) 2010-07-08
US8921410B2 (en) 2014-12-30
TWI404532B (zh) 2013-08-11
AU2007317433A1 (en) 2008-05-15
RU2009138600A (ru) 2011-04-27
JP2013056919A (ja) 2013-03-28
BRPI0717930A2 (pt) 2011-05-10
SA07280584B1 (ar) 2010-11-02
IL197618A0 (en) 2009-12-24
US20150080576A1 (en) 2015-03-19
RS51834B (en) 2012-02-29
JP2010509230A (ja) 2010-03-25
MX2009004801A (es) 2009-07-31
TWI405763B (zh) 2013-08-21
US20160039833A1 (en) 2016-02-11
AU2010219323A1 (en) 2010-09-30
EP2284171A1 (en) 2011-02-16
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
AR079840A2 (es) 2012-02-22
CO6180435A2 (es) 2010-07-19
KR20100124356A (ko) 2010-11-26
EP2094703A1 (en) 2009-09-02
ATE545646T1 (de) 2012-03-15
NZ575557A (en) 2011-01-28
ES2395157T3 (es) 2013-02-08
DK2094703T3 (da) 2011-08-29
US8114889B2 (en) 2012-02-14
UA106718C2 (uk) 2014-10-10
RU2517693C2 (ru) 2014-05-27
BRPI0722387A2 (pt) 2023-02-23
EP2094703B1 (en) 2011-05-11
CN102838605B (zh) 2017-04-26
KR101415705B1 (ko) 2014-07-04
AR063451A1 (es) 2009-01-28
JP5739398B2 (ja) 2015-06-24
EP2284171B1 (en) 2012-02-15
CA2663925A1 (en) 2008-05-15
TW201305176A (zh) 2013-02-01
IL209026A (en) 2014-03-31
RU2448969C2 (ru) 2012-04-27
CY1112374T1 (el) 2015-12-09
ATE509022T1 (de) 2011-05-15
CN101528745B (zh) 2011-09-14
HRP20110570T1 (hr) 2011-09-30
US8268860B2 (en) 2012-09-18
CN102838605A (zh) 2012-12-26
CN102942569B (zh) 2015-10-28
PT2094703E (pt) 2011-07-22
CL2007003155A1 (es) 2008-05-16
NZ587847A (en) 2011-09-30
TWI454262B (zh) 2014-10-01
US8859609B2 (en) 2014-10-14
UA98944C2 (ru) 2012-07-10
PE20110671A1 (es) 2011-10-20
CA2663925C (en) 2015-04-21
CN102020646B (zh) 2013-11-13
US20100081683A1 (en) 2010-04-01
US20130005789A1 (en) 2013-01-03
WO2008057938A1 (en) 2008-05-15
US20120289572A1 (en) 2012-11-15
IL197618A (en) 2013-09-30
CN102020646A (zh) 2011-04-20
UY30686A1 (es) 2009-08-03
MY156730A (en) 2016-03-15
AU2007317433B2 (en) 2012-05-10
HK1133260A1 (en) 2010-03-19
SI2094703T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
NZ588121A (en) Novel estrogen receptor ligands
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
PE20061295A1 (es) Derivados de acetileno
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
NO20082096L (no) Azaindol-2-karboksamidderivativer
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
EP2077846A4 (en) BENZOXAZEPINE COMPOUNDS, PREPARATION THEREOF AND USE THEREOF
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
NZ597866A (en) Therapeutic lactams
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
EA200970404A1 (ru) Соединения, проявляющие активность в отношении св
NO20072060L (no) 2-acylaminotiazolderivater
TW200626158A (en) Naphthaline derivatives
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载